January 2016

Dear shareholders and prospective shareholders,

2016 got off to a great start with the announcement of another anesthesia acquisition on the first business day of the year (see below for details).

As we look ahead, our investor relations focus this year will be to inform and educate new and existing investors on CRH’s current business operations, and expand awareness across North America of our GI focused growth strategy.

Canadian Marketing

Management spent the last week of January marketing in Toronto and Montreal, where they met with both institutional shareholders and prospective accounts. Operationally, we continue to execute on our strategy, and keeping the investment community updated on our progress helps to build a track record of credibility for the company.

I was able to join the team mid-week and spent most of my time engaging the retail investment community. This two pronged approach allows CRH to reach both an institutional and retail audience and maximize our marketing efforts. It is exciting to share the CRH story with new investors, and something that we look forward to continuing to focus on this year.

Purchase of Johns Creek Anesthesia

On January 4th, CRH Medical announced the purchase of Johns Creek Anesthesia (JCA). The acquisition further solidifies CRH’s footprint in Georgia and was integrated immediately into our existing operations. The acquisition of JCA is consistent with our growth strategy, as we continue to consolidate the large and fragmented GI anesthesia market.

GI Conferences

This past weekend, CRH attended its first conference of the year in Scottsdale, AZ. The annual ACG Governors/ASGE Best Practices course always draws in a good sized crowd and typically provides us with a solid number of new leads. This year was no exception. Once again, the CRH O’Regan System was one of the featured hemorrhoid treatment devices at the “hands-on” course, and CRH Anesthesia created interest among both trained O’Regan customers as well as new prospects.

If you have any questions, or would like an update on any aspect of our business, please don’t hesitate to contact me either by phone or email. Thank you for your continued support.

David Matousek
Director, Investor Relations
CRH Medical Corporation
T: 800.660.2153 x 1030
W: www.crhmedcorp.com
E: dmatousek@crhmedcorp.com

We're a stable, profitable company respected by both patients and physicians. Learn more »